Overview

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-10-13

Target enrollment:

Participant gender:

Summary

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

MK-0616